A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents

Applied Occupational and Environmental Hygiene

Volumn 18, Issue 2, 2003, Pages 120-131

  Larson, Rodney R ^a   Khazaeli, M B ^b   Kenneth Dillon, H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

5 Fluorouracil; Air Monitoring Methods; Antineoplastics; Cyclophosphamide; Doxorubicin HCl; HPLC; Ifosfamide; Paclitaxel; Taxol

Indexed keywords

ACTIVATED CARBON; ADRICIL; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; PACLITAXEL; POLYMETHACRYLIC ACID; SORBENT;

ACCURACY; ADSORPTION; AIRBORNE PARTICLE; AIRFLOW; ANALYTIC METHOD; ARTICLE; DESORPTION; EVALUATION; FILTER; MEASUREMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; TUBE; VALIDATION PROCESS;

EID: 0345505703     PISSN: 1047322X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10473220301435     Document Type: Article

References (31)

1. Clark, C.: Seminar - Occupational Exposure to Cytotoxic Drugs. Carmel Pharma AB, Stockholm. Pharm J 263 (July 1999).
2. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals in Humans: IARC Monographs. Vols. 1-29. Lyons, France, International Agency for Research on Cancer (1982).
3. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans - Overall Evaluations of Carcinogenicity, and Updating of IARC Monographs. Vols. 1 to 42, Supplement 7. Lyons, France, International Agency for Research on Cancer (1987).
4. Benedict, W.F.; Baker, M.S.; Haroun, L.; et al.: Mutagenicity of Cancer Chemotherapeutic Agents in the Salmonella/Microsome test. Cancer 37:2203-2213 (1977).
5. Harris, C.C.: The Carcinogenicity of Anticancer Drugs: A Hazard in Man. Cancer 37:1014-1023 (1976).
6. Purdom, C.E.: Mutagenic Effects of Nitrogen Mustard Derivative of Azobenzene Compounds in Drosophila Melanogaster. Biochem Pharmacol 5:206-218 (1960).
7. Toledo, T.M.; Harper, R.C.; Moser, R.H.: Fetal Effects During Cyclophosphamide and Irradiation Therapy. Ann Intern Med 74:87-91 (1971).
8. Lewis, R.J.; Hazardous Chemicals Desk Reference, 2nd ed. Van Nostrand Reinhold, New York (1990).
9. Cytoxan (Cyclophosphamide) Rx Information Sheet: MeadJohnson Oncology Products. Bristol-Myers Squibb Co., Princeton, NJ (1998).
10. Cyclophosphamide Material Safety Data Sheet. Bristol-Myers Squibb, Pharmaceutical & Nutritional Group, Evansville, IN (1990).
11. Cytoxan MSDS: Cytoxan for Injection - Cyclophosphamide for Injection. Bristol-Myers Squibb U.S. Pharmaceutical & Nutritional Group, Evansville, IN (1990).
12. IFEX (Ifosfamide) Rx Information Sheet.: MeadJohnson Oncology Products. Bristol-Myers Squibb Co., Princeton, NJ (1997).
13. Adrucil (Fluorouracil Injection, USP) Rx Information Sheet. Pharmacia & Upjohn Company, Kalamazoo, MI (1997).
14. Doxorubicin HCl for Injection Rx Information Sheet. Ben Venue Laboratories, Inc. Manufactured for Bedford Laboratories, Bedford, OH (1998).
15. Taxol (Paclitaxel) Rx Information Sheet.: MeadJohnson Oncology Products. Bristol-Myers Squibb Co., Princeton, NJ (1998).
16. Pyy, L.; Sorsa, M.; Hakala, E.: Ambient Monitoring of Cyclophosphamide in Manufacture and Hospitals. Am Indus Hyg Assoc J 49:314-317 (1988).
17. McDevitt, J.J.; Lees, P.S.J; McDiarmid, M.A.: Exposure of Hospital Pharmacists and Nurses to Antineoplastic Agents. J Occup Med 35:57-60 (1993).
18. Sessink, P.J.M.; Boer, K.A.; Scheefhals, A.P.H.; et al.: Occupational Exposure to Antineoplastic Agents at Several Departments in a Hospital: Environmental Contamination and Excretion of Cyclophosphamide and Ifosfamide in Urine of Exposed Workers. Int Arch Occup Environ Health 64:105-112 (1992).
19. Sessink, P.J.M.; deRoos, J.H.C.; Pierik, F.H.; et al.: Occupational Exposure of Animal Caretakers to Cyclophosphamide. J Occup Med 35(1) (January 1993).
20. Sessink, P.J.M.; Bos, B.P.: Drugs Hazardous to Healthcare Workers: Evaluation of Methods for Monitoring Occupational Exposure to Cytostatic Drugs. Drug Safety 20(4):347-359 (1999).
21. McDiarmid, M.A.; Egan, T.; Furio, M.; et al.: Sampling for Airborne Fluorouracil in a Hospital Drug Preparation Area. Am J Hosp Pharm 43(8):1942-1495 (1988).
22. Neal, A.D.; Wadden, R.A.; Chiou, W.L.: Exposure of Hospital Workers to Airborne Antineoplastic Agents. Am J Hosp Pharm 40:597-601 (1983).
23. National Sanitation Foundation. Standard No. 49 for Class II (Laminar Flow) Biohazard Cabinetry. NSF, Ann Arbor, MI (1990).
24. Connor, T.H.; Anderson, R.W.; Sessink, P.J.M.; Broadfield, L.; Power, L.A.: Surface Contamination with Antineoplastic Agents in Six Cancer Treatment Centers in Canada and the United States. Am J Health-System Pharm 56:1427-1432 (1999).
25. Waters Corp: HPLC Analytical Information. Waters HPLC 99 Scientific Program, Barcelona, Spain (1999).
26. Taylor, D.E.; Kupel, R.E.; Bryant, J.M.: Documentation of the NIOSH Validation Tests (DHEW/NIOSH). Pub. No. 77-175. U.S. Government Printing Office, Washington, DC (1977).
27. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. NIOSH Manual of Analytical Methods, 4th Ed. National Institute for Occupational Safety and Health, Cincinnati, OH (1994).
28. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Recommendations for the Safe Handling of Cytotoxic Drugs. NIH Publication no. 92-2621. National Institutes of Health, Bethesda, MD (1992).
29. Sorsa, M.; Hemminki, K.; Vanio, H.: Occupational Exposure to Anticancer Drugs - Potential and Real Hazards. Mutation Res 154:135-149 (1985).
30. Stanetzek, I.; Ulrich, G.; Schuster, R.H.; et al.: Chromatographic Characterization of Adsorbents for Selective Sampling of Organic Air Pollutants. Am Indus Hyg Assoc J 57:128-133 (1996).
31. Harper, M.: Methods of Characterizing Sorbents for Air Sampling Purposes, Fundamentals of Adsorption 1993. Proc. IVth Int. Conf. on Fundamentals of Adsorption, Kyoto, Japan, May 17-22 (1993).